

. (Formerly known as Orchid Chemicals & Pharmaceuticals Limited) Corp. Off.: Orchid Pharma Ltd., 'Orchid Towers' 313, Valluvarkottam High Road, Nungambakkam, Chennai - 600 034. India. CIN: L24222TN1992PLC022994

June 09, 2021

National Stock Exchange of India Ltd	BSE Limited
Listing Department	Corporate Relationship Department
Exchange Plaza, 5th Floor, Plot No: C/1,	1st floor, New Trading Ring, Rotunda Building,
G - Block, Bandra — Kurla Complex,	P J Towers, Dalal Street, Fort
Bandra (East), Mumbai - 400 051	Mumbai - 400 001
NSE Symbol: ORCHPHARMA	BSE Code: 524372
Luxembourg Stock Exchange	London Stock Exchange
Bourse de Luxembourg	10 Paternoster Square
BP 165, L-2011 Luxembourg Siege social	London
11, avenue de la Portal - Neuve	EC4M 7LS
	United Kingdom

Subject: Corporate presentation of Orchid Pharma Limited

Dear Sir / Madam

In terms of the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("**SEBI Listing Regulations**"), please find attached the corporate presentation on our Company. The presentation shall also be made available on our website.

We request you to take the above on record and that the same be treated as compliance under the applicable regulation(s) under the SEBI Listing Regulations.

Thanking you,

Yours faithfully,

For Orchid Pharma Limited

Company secretary



The Turnaround Story



COMPANY OVERVIEW

•••••••

PIONEER IN CEPHALOSPORIN ANTIBIOTICS

R&D Focused, Inventor of Enmetazobactam (Ph.-3 Trials done in US & EU) Acquired by Dhanuka Group through CIRP Process on 1st April 2020

ABOUT DHANUKA GROUP

~ 2500 Crore diversified group. interests in Crop Care and Pharma Dhanuka Laboratories is the Pharma arm. More than 20 years experience in Antibiotics space

INTEGRATED CEPHALOSPORIN API COMPANY SPREAD OVER 60 ACRES Worldwide approvals from USFDA, EU, ANVISA, PMDA Widest Portfolio of > 25 products across Oral and Sterile Cephalosporins

PROFESSIONAL & EXPERIENCED BOARD WITH STRONG MANAGEMENT TEAM

Over 200 years experience in the board.

Over 1000 strong team, with Managers 15 years experience at Orchid.

STRONG R&D CAPABILITIES


Capability to file Para IV applications with USFDA with 8 FTF till date More than 10 process patents and 13 product patents

GLOBAL PRESENCE WITH A WIDE CUSTOMER BASE

Present in more than 50 Countries More than 200 Customers across US, Europe and Emerging Markets

FOCUS ON ESG

Highest Standards of Air – Water Emission Control – ZLD – 70% Recycle Community development programs for Villages around the company





HISTORY

.....

1992

Orchid was Formed

2005

First USFDA Approval FDF Facility Inaugurated by Dr. APJ Abdul Kalam

2008

First ANDA Approval Partnership with Merck for Drug Discovery

2009

First Para-IV filing for Pip-Taz in collaboration with Apotex Sells Injectables business to Hospira for \$400mn

2013

Sells NPNC API business to Hospira for \$200mn Out-license Enmetazobactum to Allecra





BACKGROUND AND PEDIGREE

.....

DHANUKA AGRITECH LTD



- Flagship of the Group founded in 1980.
- Listed on Stock Exchanges for 35 years with a Market Cap of USD 600mn
- Manufactures a wide range of farm input products
- The Company has pan India presence with a network of more than 6000 distributors reaching out to more than 10 million farmers
- The Company has technical tie ups with 4 American and 6 Japanese companies

DHANUKA LABORATORIES LTD.


dhanuka

- Pharmaceutical Arm started in 1998.
- Leader in Cephalosporin Antibiotics in Emerging markets.
- JV with Otsuka Japan, for manufacturing advanced intermediates.
- 2 API Manufacturing Facilities, both Cephalosporin and NPNC.
- NPNC Facility started in 2018, equipped for all regulated markets.
- Formulations exports to emerging markets.



KEY RATIONALE FOR ACQUIRING ORCHID PHARMA

.....



Orchid and Dhanuka complement each other to become formidable force in APIs



ANTIBIOTICS


....

THE LIFE SAVING DRUGS

Global Antibiotics Market in 2019 – USD 43 bn

Cephalosporins is the Largest class with 30% share.

Cephs have Excellent Safety profile and wide
coverage of gram-negative bacteria in 3rd generation products onwards.











WIDEST RANGE OF CEPHALOSPORINS





GLOBAL PRESENCE WITH A WIDE CUSTOMER BASE

.....





LARGEST INTEGRATED CEPHALOSPORIN API COMPANY

.....

- Integrated facilities from Intermediate to finished 60 Acre
- Sterile 3 Lines Sterile Crystalline and 1 Lyophilized
- Oral 7 Blocks with multiple lines
- Intermediates 5 Blocks with multiple lines
- Total Capacity 900MT
- Worldwide approvals







FINISHED DOSAGE FACILITIES

.....



IKKT

- USFDA / UKMHRA Certified
- 29 ANDAs with associated DMFs
- Exporting to US / EU Markets
- Now Hived off to associate JV Company

F1


- Was a small Cephalosporin Operation
- Now being upgraded to meet PICS standards
- Will focus on Oral Ceph FDF for Exports





STRONG R&D CAPABILITIES

......



ORCHID PHARMA HAS BEEN FOCUSED ON R&D, WILL CONTINUE TO INVEST IN IT.



BOARD OF DIRECTORS

.....

BOARD OF DIRECTORS



Mr. Ram Gopal Agarwal Chairman and Non-Executive Director ~Founder Chairman of Dhanuka Group; Over 5 decades of leadership ~Chairman of FICCI Crop Protection Committee



Mr. Manish Dhanuka Managing Director ~Visionary Leader at the helm of affairs of Pharma Division. ~An IIT'ian with 25+ years in Pharma Industry; ~Director at JV with Otsuka Japan.



Mr. Arun Kumar Dhanuka Non-Executive Director ~Director at DLL, DAL and Orchid; Over 4 decades of experience ~In-charge of commercial matters of the Pharma Division;



Mr. Mridul Dhanuka Whole-Time Director

~Chemical Engineer & MBA; Associated with Dhanuka Group Ltd. since 2005. ~Operations Head at Dhanuka Agritech, now moved to Orchid.



Independent Director ~Ph.D. in Synthetic Chemistry. ~More than 3 decades of R&D experience at various Pharma Majors



CA Manoj Goyal Independent Director ~Practicing CA ~Auditor of Banks and other large businesses.



Mr. Mudit Tandon Independent Director ~Graduate of ISB and worked in Venture Capital field. ~Runs a large fashion

~Runs a large fashion accessory company.



Ms. Tanu Singla Independent Director ~Qualified Company Secretary, L.L.B

LEADERSHIP AND SENIOR MANAGERIAL PERSONNEL



CA Sunil Gupta

Dr Dharam Vir

CFO ~ Chartered Accountant ~35 Years of experienced in varied industries as financial controller.



Dr. UP Senthilkumar Sr. VP R&D - IPM ~Co-Inventor of Enmetazobactum ~Responsible for noninfringing process developments. Several Patents



Dr. RJ Sarangdhar Site Head of Ceph API ~3 decades of experience in process development, technology transfer. ~More than 10 patents to his credit.




Mr. S Nammalwar Manufacturing Excellence ~Over 3 decades of experience of leading complex chemical industries. ~Responsible for Excellence in all Manufacturing areas.



FOCUS ON ESG

......





COMMITMENT TO ENVIRONMENT

.....

WATER

- Advanced Evaporation and RO Systems
- ZERO Liquid Discharge
- 70% of fresh Water is recycled after recovery



AIR

- Vent Gas Scrubbing System
- Highest Possible Recovery @ -80deg Centigrade
- No fugitive Emissions
- ESP / Venturi Filters for Particle Arrest





FUTURE STRATEGY



STRATEGY FOR ORCHID API BUSINESS

......



Priority to scale up current business and improve capacity utilisation




PROPOSAL TO CONSOLIDATE GROUP'S API BUSINESSES UNDER A SINGLE UMBRELLA

STRATEGY - TO ATTAIN LEADERSHIP IN APIS

•••••••

• Business Consolidation Committee formed to evaluate the consolidation of Dhanuka Laboratories Limited with Orchid.

- This consolidation was part of the Resolution Plan submitted to NCLT
- Merger Form Single entity for all Pharma Business Good Corporate Governance
- The transaction shall be done at arm length basis, approved by minority shareholders.



Forward integration for API business, to make Orchid a Global leader in Ceph formulations





PROUD MOMENT FOR INDIA FIRST PRODUCT INVENTED IN INDIA, TO CLEAR PH.-3-ENMETAZOBACTUM

.....

- In 2013, Orchid out licensed a NCE Enmetazobactum to Allecra Therapeutics, Germany for Clinical Trials. Cleared the Phase 3 trials in October 2020.
- This is a Unique Beta Lactamase Inhibitor, in combination with Cefepime.
- Targeted for treating cUTI with over 24Mn DOT just in US market.
- December 2020, out-licensed to Shanghai Haini Pharmaceuticals for Greater China at a value of USD 78 Mn plus royalties
- Estimate annual global sales of USD 200 Mn –300 Mn (10Y Avg)
- Orchid entitled to Royalty from Allecra ~ USD 16 Mn USD 25 Mn pa
- Orchid has rights to develop and commercialize the molecule in India.
 - Company plans to file New Drug Application in India, after Covid crises.



